The Living Guidelines: Patients with Cardiac Structural Abnormalities or Remodeling who have not Developed Heart Failure Symptoms. Polling Results for CLASS III Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class III Guidelines
1. Digoxin should not be used in patients with low EF, sinus rhythm, and no history of HF symptoms, because in this population, the risk of harm is not balanced by any known benefit. (Level of Evidence: C)

 ACC / AHA Guidelines for Diagnosis and Management of Chronic Heart Failure: Class III Recommendation 1 for patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms should be: CLASS I CLASS IIa CLASS IIb CLASS III 2. Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is not recommended. (Level of Evidence: C)

 ACC / AHA Guidelines for Diagnosis and Management of Chronic Heart Failure: Class III Recommendation 2 for patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms should be: CLASS I CLASS IIa CLASS IIb CLASS III 3. Calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of HF after MI (Patients in Stage C). (Level of Evidence: C)

 ACC / AHA Guidelines for Diagnosis and Management of Chronic Heart Failure: Class III Recommendation 3 for patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms should be: CLASS I CLASS IIa CLASS IIb CLASS III